Clinical Trial Update: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL [Phase 1, Phase 2]

View source ↗

Summary

Update on a CD30-targeted CAR-T cell therapy being studied for relapsed/refractory Hodgkin lymphoma and CD30+ Non-Hodgkin lymphoma in Phase 1/Phase 2 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD30 CAR-T

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Lymphoma, Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING